Naproxen: Difference between revisions
(Text replacement - "*CHF" to "*CHF") |
|||
| Line 29: | Line 29: | ||
*Angioedema | *Angioedema | ||
*Bronchospasm | *Bronchospasm | ||
*CHF, pulmonary edema | *[[CHF]], pulmonary edema | ||
*Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis | *Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis | ||
*Vasculitis | *Vasculitis | ||
Revision as of 11:44, 24 September 2016
Administration
- Type: NSAID
- Dosage Forms:
- Routes of Administration: PO
- Common Trade Names: Aleve
Adult Dosing
- 500mg PO BID OR 250mg q6-8h
Pediatric Dosing
- 5mg/kg BID
Special Populations
- Pregnancy Rating: C
- Lactation risk: infant risk minimal
Renal Dosing
- Adult: Not recommended if CrCl <30
- Pediatric:
Hepatic Dosing
- Adult: use lowest effective dose
- Pediatric:
Contraindications
- Allergy to class/drug
- peri-CABG
Adverse Reactions
Serious
- GI bleed, gastric ulcer
- Nephrotoxicity
- Angioedema
- Bronchospasm
- CHF, pulmonary edema
- Thrombocytopenia, aplastic anemia, hemolytic anemia, agranulocytosis
- Vasculitis
- SJS/TEN
- Hepatotoxicity (hepatitis, liver failure)
- Aseptic meningitis, seizure
Common
- Nausea, heartburn, constipation
- Edema
- Ecchymosis
- Headache
- Ototoxicity
Pharmacology
- Half-life: 12-17 hours
- Metabolism:
- Excretion: Renal
Mechanism of Action
- NSAID